138 related articles for article (PubMed ID: 36122671)
1. Comparison of renal safety and bone mineral density of tenofovir and entecavir in patients with chronic hepatitis B: a systematic review and meta-analysis.
Yang X; Yan H; Zhang X; Qin X; Guo P
Int J Infect Dis; 2022 Nov; 124():133-142. PubMed ID: 36122671
[TBL] [Abstract][Full Text] [Related]
2. Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis.
Liu Z; Zhao Z; Ma X; Liu S; Xin Y
BMC Gastroenterol; 2023 Nov; 23(1):384. PubMed ID: 37950196
[TBL] [Abstract][Full Text] [Related]
3. Comparison of renal safety of tenofovir and entecavir in patients with chronic hepatitis B: Systematic review with meta-analysis.
Lee HY; Oh H; Park CH; Yeo YH; Nguyen MH; Jun DW
World J Gastroenterol; 2019 Jun; 25(23):2961-2972. PubMed ID: 31249453
[TBL] [Abstract][Full Text] [Related]
4. Improved bone and renal safety in younger tenofovir disoproxil fumarate experienced chronic hepatitis B patients after switching to tenofovir alafenamide or entecavir.
Da Wang F; Zhou J; Li LQ; Li YJ; Wang ML; Tao YC; Zhang DM; Wang YH; Chen EQ
Ann Hepatol; 2023; 28(5):101119. PubMed ID: 37271480
[TBL] [Abstract][Full Text] [Related]
5. Antiviral therapy and the development of osteopenia/osteoporosis among Asians with chronic hepatitis B.
Wei MT; Le AK; Chang MS; Hsu H; Nguyen P; Zhang JQ; Wong C; Wong C; Cheung R; Nguyen MH
J Med Virol; 2019 Jul; 91(7):1288-1294. PubMed ID: 30776311
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the Efficacy of Tenofovir Versus Tenofovir plus Entecavir in the Treatment of Chronic Hepatitis B in Patients With Poor Efficacy of Entecavir: A Systematic Review and Meta-analysis.
Chen J; Zhao SS; Liu XX; Huang ZB; Huang Y
Clin Ther; 2017 Sep; 39(9):1870-1880. PubMed ID: 28797777
[TBL] [Abstract][Full Text] [Related]
7. Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis.
Huang ZH; Lu GY; Qiu LX; Zhong GH; Huang Y; Yao XM; Liu XH; Huang SJ; Wu T; Yuan Q; Wang YB; Su YY; Zhang J; Xia NS
BMC Cancer; 2022 Mar; 22(1):287. PubMed ID: 35300634
[TBL] [Abstract][Full Text] [Related]
8. Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial.
Lim YS; Gwak GY; Choi J; Lee YS; Byun KS; Kim YJ; Yoo BC; Kwon SY; Lee HC
J Hepatol; 2019 Jul; 71(1):35-44. PubMed ID: 30876946
[TBL] [Abstract][Full Text] [Related]
9. Long-term treatment with tenofovir in Asian-American chronic hepatitis B patients is associated with abnormal renal phosphate handling.
Tien C; Xu JJ; Chan LS; Chang M; Lim C; Lee S; Huh B; Shinada S; Bae HS; Fong TL
Dig Dis Sci; 2015 Feb; 60(2):566-72. PubMed ID: 25239496
[TBL] [Abstract][Full Text] [Related]
10. A novel evidence of serial changes of bone mineral density in chronic hepatitis B patients treated with entecavir.
Huang PY; Chiu SY; Chang KC; Tseng PL; Yen YH; Tsai MC; Wang JH; Kee KM; Chen CH; Hung CH; Chiu KW; Hu TH
Hepatol Int; 2021 Apr; 15(2):310-317. PubMed ID: 33907949
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of tenofovir disoproxil fumarate versus entecavir in the treatment of acute-on-chronic liver failure with hepatitis B: a systematic review and meta-analysis.
Wang N; He S; Zheng Y; Wang L
BMC Gastroenterol; 2023 Nov; 23(1):388. PubMed ID: 37957546
[TBL] [Abstract][Full Text] [Related]
12. Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B.
Jeong S; Shin HP; Kim HI
Intervirology; 2022; 65(2):94-103. PubMed ID: 34731856
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the renal safety of tenofovir disoproxil fumarate in hepatitis B patients without chronic kidney disease.
Tsai HJ; Chuang YW; Yang SS; Chang YZ; Chang HR; Lee TY
J Viral Hepat; 2021 Nov; 28(11):1579-1586. PubMed ID: 34464999
[TBL] [Abstract][Full Text] [Related]
14. Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year, multicentre retrospective cohort study.
Lampertico P; Berg T; Buti M; Pathil A; Petersen J; Ryder SD; Zoulim F; Botros I; Flaherty JF; Jump B; Op den Brouw ML; van Troostenburg A; Ramroth H;
Aliment Pharmacol Ther; 2020 Aug; 52(3):500-512. PubMed ID: 32583915
[TBL] [Abstract][Full Text] [Related]
15. Using the chronic kidney disease guidelines to evaluate the renal safety of tenofovir disoproxil fumarate in hepatitis B patients.
Tsai HJ; Chuang YW; Lee SW; Wu CY; Yeh HZ; Lee TY
Aliment Pharmacol Ther; 2018 Jun; 47(12):1673-1681. PubMed ID: 29696665
[TBL] [Abstract][Full Text] [Related]
16. Long-term use of tenofovir disoproxil fumarate increases fracture risk in elderly patients with chronic hepatitis B.
Yip TC; Lai JC; Yam TF; Tse YK; Hui VW; Lai MS; Chan HL; Wong VW; Wong GL
J Hepatol; 2024 Apr; 80(4):553-563. PubMed ID: 38101755
[TBL] [Abstract][Full Text] [Related]
17. Tenofovir monotherapy versus tenofovir plus entecavir combination therapy in HBeAg-positive chronic hepatitis patients with partial virological response to entecavir.
Wang YH; Liao J; Zhang DM; Wu DB; Tao YC; Wang ML; Chen EQ; Tang H
J Med Virol; 2020 Mar; 92(3):302-308. PubMed ID: 31609007
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety comparison between tenofovir and entecavir in treatment of chronic hepatitis B and HBV related cirrhosis: A systematic review and Meta-analysis.
Han Y; Zeng A; Liao H; Liu Y; Chen Y; Ding H
Int Immunopharmacol; 2017 Jan; 42():168-175. PubMed ID: 27915131
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the side effects of antivirals in chronic hepatitis B patients: a single-center experience.
Gok Sargin Z; Celik U; Dusunceli I; Ustundag Y
Acta Gastroenterol Belg; 2022; 85(4):587-592. PubMed ID: 36566368
[TBL] [Abstract][Full Text] [Related]
20. Altered Underlying Renal Tubular Function in Patients With Chronic Hepatitis B Receiving Nucleos(t)ide Analogs in a Real-World Setting: The MENTE Study.
Rodríguez-Nóvoa S; García-Samaniego J; Prieto M; Calleja JL; Pascasio JM; Delgado Blanco M; Crespo J; Buti M; Bonet Vidal ML; Arenas Ruiz Tapiador J; Fernández-Rodríguez C; Solá R; Fraga E; González Diéguez L; Núñez O; Praga M; Del Pino-Montes J; Romero-Gómez M; Morillas R; Diago M; Castro Á;
J Clin Gastroenterol; 2016 Oct; 50(9):779-89. PubMed ID: 27332746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
